Search Results

September 21, 2021

Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.

Additional data show a booster increases protection 94 percent protection in the U.S. with booster given at two months Four-fold increase in antibodies when given at two months 12-fold increase in antibodies when booster given at six months

Innovative Medicine

September 17, 2021

Janssen Presents Results from Phase 1b/2 NORSE Study in Patients with Metastatic or Locally Advanced Urothelial Carcinoma Treated with BALVERSA® (erdafitinib) in Combination with Cetrelimab, a PD-1 Inhibitor

Oral presentation at ESMO Annual Congress 2021 – featured in a late-breaking abstract – reports efficacy and safety of BALVERSA® in combination with a PD-1 inhibitor in bladder cancer

Global health equity

September 13, 2021

Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases

Data show the vaccine regimen induced neutralizing antibody responses in nearly all participating adults and children 21 days after the second dose Adults receiving booster shots two years after initial vaccination regimen showed strong immune responses The data support the potential prophylactic use of the Johnson & Johnson Ebola vaccine regimen to protect adults and children

Innovative Medicine

September 8, 2021

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress

Data for approved and investigational treatments to be presented in bladder cancer, lung cancer and prostate cancer Investigational RYBREVANT® (amivantamab-vmjw) and lazertinib combination therapy in epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) to be featured in oral presentations

Innovative Medicine

September 1, 2021

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA™ (6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia

INVEGA HAFYERA™ offers patients the fewest doses per year for a life less defined by schizophrenia medication Phase 3 non-inferiority study results showed over 92% of participants were relapse-free at 12 months Approval is backed by nearly two decades of proven efficacy and safety of Janssen’s long-acting injectable portfolio of schizophrenia medicines

Corporate

August 26, 2021

Johnson & Johnson Seeks Global Nominees for Award Geared at Female Researchers Working in Science, Technology, Engineering, Math, Manufacturing and Design

The Women in STEM2D (WiSTEM2D) Scholars Award honors female scholars with $150,000 grant and three years of mentorship Deadline for applications is Sept. 27, 2021

Innovative Medicine

August 24, 2021

FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD

XARELTO® is the first and only therapy indicated for both coronary artery disease (CAD) and PAD, now including PAD patients post-LER XARELTO® is the only anticoagulant in 20 years to show significant benefit in patients with PAD who remain at high risk for major thrombotic events, including acute limb ischemia and amputation PAD impacts 20 million Americans1 and is the leading cause of amputations in the U.S., with rates continuing to rise2

Innovative Medicine

July 30, 2021

UPTRAVI® (selexipag) Receives FDA Approval for Intravenous Use in Adult Patients with Pulmonary Arterial Hypertension (PAH)

New formulation allows for uninterrupted treatment for PAH patients temporarily unable to take oral therapy

Innovative Medicine

July 9, 2021

STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial

55.2 percent of patients were in symptomatic remission and 96.4 percent of patients were corticosteroid-free at week 152 New data from the UNIFI study is one of 22 Janssen abstracts, including five oral and three digital oral presentations, at the 16th Congress of the European Crohn’s and Colitis Organisation

Global health equity

July 9, 2021

Johnson & Johnson Launches Network of Global Health Discovery Centers that Aim to Speed Up Science and Tackle Pandemic Threats

J&J Centers for Global Health Discovery (J&J Centers) are a new cornerstone of the Company’s efforts to solve the world’s most pressing health challenges The first J&J Satellite Center is hosted at the London School of Hygiene & Tropical Medicine (LSHTM) and focused on addressing the threat of antimicrobial resistance and tuberculosis J&J Centers will include collaborations with renowned academic institutions that accelerate potentially lifesaving innovations from the lab to the last mile

Search Results

No Results

Search Results

You are now leaving jnj.com/innovativemedicine